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Case Report
Ziprasidone is effective for the acute and maintenance
treatment of schizophrenia, as well as for the treatment of
acute mania. It generally has a benign adverse effects pro-
file. However, cases of mania associated with the initia-
tion of treatment with ziprasidone have been reported. In
the present study we present three cases of hypomania
and mania associated with the initiation of ziprasidone
administration.
Case 1
Mr A. is a 20 year-old man with schizophrenia, paranoid
type, who received ziprasidone after five weeks of unsuc-
cessful treatment with olanzapine up to 30 mg/day. After
ten days, when the dose of ziprasidone had been gradu-
ally titrated up to 160 mg/day, he presented hyperthymia,
irritability, psychomotor agitation, pressure of speech,
grandiose delusions, decreased need for sleep, and sexual
indiscretion (public masturbation). After an episode of
physical assault against two other patients, Mr A. was
restrained and ziprasidone was replaced with haloperidol
IM and then per os. Two weeks later, the patient exhibited
significant improvement of his behaviour, but persecu-
tory and grandiose delusions, as well as auditory halluci-
nations, remained unchanged.
Case 2
Mr B. is a 47 year-old man with schizophrenia, paranoid
type, who after a short period of treatment with haloperi-
dol IM received ziprasidone (80 mg/day). After four days,
expansive mood, delusions of grandiosity and pressure of
speech were added to his psychopathology. Finally, about
three weeks after ziprasidone initiation, the patient left
the hospital without permission. Eight days later, he was
brought back to hospital and haloperidol per os was
administered, resulting in sufficient control of his symp-
toms 10 days later.
Case 3
Mr C. is a 31 year-old man with schizophrenia, undiffer-
entiated type, in whom risperidone (8 mg/day) was
replaced with ziprasidone (80 mg/day). Three days later,
he manifested elated mood accompanied by an increase
in goal-directed activity, which later progressed to severe
agitation, sexual indiscretions, and unrestrained money
waste. Simultaneously, the patient displayed decreased
need for sleep and grandiose delusions. Two months after
ziprasidone initiation, its dose was raised to 160 mg/day,
but fifteen days later no improvement was observed.
Finally, ziprasidone was replaced with olanzapine (15
mg/day), with which his symptoms were effectively con-
trolled after 3 days.
There is evidence that atypical antipsychotics, speciffically
risperidone, olanzapine and zipresidone, induce (hypo)
manic switches. Manic symptoms caused by olanzapine
and risperidone are probably related to their 5HT2/D2
receptor occupancy. Ziprasidone is not only a potent sero-
tonin (5HT2A) and dopamine (D2) receptor antagonist,
but also an antagonist of 5HT1D and 5HT1A receptors, as
well as of norepinephrine and serotonin reuptake pumps.
Perhaps the tricyclic-like antidepressant pharmacological
profile of the drug, which is comparable to that of
amitriptyline and imipramine, might additionally explain
why in some patients it precipitates mania.
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